CSTL icon

Castle Biosciences

25.56 USD
+0.24
0.95%
At close Updated Mar 13, 4:00 PM EDT
1 day
0.95%
5 days
-4.66%
1 month
-22.9%
3 months
-34.26%
6 months
18.22%
Year to date
-33.68%
1 year
36.25%
5 years
-61.14%
10 years
19.44%
 

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Employees: 883

0
Funds holding %
of 8,077 funds
0
Analysts bullish %
of 4 analysts
0
Positive news %
of 9 articles
Price charts implemented using Lightweight Charts™